Benefits
Bypasses MTHFR Conversion
Methylfolate IS the active end-product of folate metabolism — bypasses methylenetetrahydrofolate reductase (MTHFR) enzyme entirely. ~30-50% of the population has MTHFR C677T or A1298C variants reducing enzyme activity 30-70%; these individuals convert folic acid less efficiently. Methylfolate provides bioavailable folate regardless of MTHFR status.
Homocysteine Lowering
Methylfolate is required for converting homocysteine to methionine via methionine synthase + B12. Elevated homocysteine is independent CV risk factor. Methylfolate reduces homocysteine more reliably than folic acid in MTHFR variant carriers.
Pregnancy / Neural Tube Defect Prevention
Adequate folate prevents neural tube defects (spina bifida, anencephaly). Most prenatal vitamins use folic acid; methylfolate is preferred for women with MTHFR variants. ACOG accepts both forms; methylfolate is reasonable evidence-based choice.
Treatment-Resistant Depression Adjunct
L-Methylfolate (Deplin®, prescription medical food) at 7.5-15 mg/day has FDA medical food status as adjunct to SSRIs for major depressive disorder. Papakostas 2012 trials showed augmentation benefit. Mechanism: monoamine neurotransmitter synthesis (serotonin, dopamine, norepinephrine) requires methylfolate.
Methylation Support
Methylfolate donates methyl groups via SAMe regeneration — supports DNA methylation, neurotransmitter synthesis, phospholipid synthesis (phosphatidylcholine), creatine synthesis. Critical for one-carbon metabolism.
Mechanism of action
End-Product of Folate Metabolism
Folic acid → DHF → THF → 5,10-methyleneTHF → 5-MTHF (via MTHFR). Methylfolate IS 5-MTHF — bypasses all upstream conversions including the rate-limiting MTHFR step.
Methionine Cycle / Homocysteine Conversion
5-MTHF + homocysteine → methionine + THF (via methionine synthase, B12-dependent). Methionine becomes SAMe — universal methyl donor for >100 methyltransferase reactions.
MTHFR Variant Biology
C677T variant: ~70% reduced enzyme activity (homozygous); ~35% reduced (heterozygous). A1298C variant: similar reduction. Combined CT/AC genotype reduces activity ~50-70%. Affects ~25-50% of population varying by ethnicity (higher in Hispanic, Mediterranean populations).
Neurotransmitter Synthesis
Methylfolate provides methyl groups for tetrahydrobiopterin (BH4) regeneration — BH4 is cofactor for tyrosine hydroxylase and tryptophan hydroxylase, the rate-limiting enzymes in dopamine and serotonin synthesis.
Clinical trials
Two sequential RCTs of L-methylfolate (7.5-15 mg) augmentation to SSRIs in SSRI-resistant major depressive disorder. (Papakostas et al. 2012, Am J Psychiatry)
SSRI-resistant MDD patients.
L-methylfolate 15 mg/day significantly improved depression scores vs SSRI alone in second trial. 7.5 mg dose did not separate from placebo. FDA medical food status (Deplin®) granted based on this evidence. Subgroup with low folate or high BMI/inflammation responded best.
Comparative trial of L-5-MTHF vs folic acid for homocysteine reduction in healthy women.
Healthy women.
Both forms reduced homocysteine; L-5-MTHF produced higher plasma folate levels than equivalent folic acid dose. Particularly notable in MTHFR C677T variant carriers — methylfolate bypasses the impaired enzyme.
About this ingredient
Methylfolate (L-5-methyltetrahydrofolate, L-5-MTHF) is the BIOACTIVE END-PRODUCT of folate metabolism — bypasses the entire conversion cascade including the rate-limiting MTHFR enzyme step.
CRITICAL DISTINCTION FROM FOLIC ACID: folic acid is a SYNTHETIC oxidized form that requires multi-step enzymatic reduction (folic acid → DHF → THF → 5,10-methyleneTHF → 5-MTHF); MTHFR enzyme variants (C677T, A1298C) significantly impair this conversion in ~30-50% of population. Methylfolate IS 5-MTHF — directly usable. BRANDED FORMS: (1) QUATREFOLIC® (Gnosis) — glucosamine salt; high stability and bioavailability; (2) METAFOLIN® (Merck) — calcium salt; well-established.
RDA: 400 µg DFE/day adults; 600 µg DFE pregnancy.
UL: 1,000 µg from supplemental forms (food folate not counted). PHARMACEUTICAL FORM: DEPLIN® (l-methylfolate calcium 7.5 or 15 mg) is FDA medical food for major depressive disorder adjunct.
EVIDENCE-BASED USES: (1) MTHFR variant carriers needing folate repletion; (2) Pregnancy / neural tube defect prevention; (3) Homocysteine lowering (CV risk reduction); (4) Treatment-resistant depression adjunct (Deplin® / Papakostas 2012); (5) General methylation support.
CRITICAL CAUTIONS: (1) B12 DEFICIENCY MASKING — high folate can mask megaloblastic anemia from B12 deficiency while neurological damage progresses; ALWAYS pair with B12; check B12 status; (2) OVERMETHYLATION — sensitive individuals (especially COMT slow variants) may experience anxiety, irritability, insomnia at high doses; start low; (3) METHOTREXATE INTERACTION — folate antagonist chemotherapy; consult oncologist before supplementing; (4) ANTICONVULSANTS — reduce folate; supplementation may reduce drug efficacy; consult neurologist; (5) PREGNANCY — RDA is 600 µg DFE; methylfolate appropriate; (6) MTHFR TESTING — 23andMe and similar consumer tests report MTHFR genotype; clinical relevance moderate (not all carriers symptomatic); (7) HOMOZYGOUS C677T carriers may benefit most from methylfolate over folic acid; (8) DOSE — 400-800 µg DFE for general use; 7.5-15 mg only for prescribed MDD adjunct; (9) FOLIC ACID FORTIFICATION (US, Canada, many countries) provides population-level folate adequacy — methylfolate supplementation is for specific clinical contexts not population-wide replacement.